ImmuPharma- Plc (IMM:LSE) Annual Reports & Investor Relations Material

Overview

ImmuPharma is a London-based biopharmaceutical company that specializes in peptide-based therapeutics for a range of therapy areas, including autoimmunity, metabolism, anti-infectives, and cancer. The company's lead product candidate is Lupuzor, which is designed to treat lupus, an autoimmune chronic inflammatory disease, and is currently in Phase III clinical trials. ImmuPharma also has other product candidates, including IPP-204106, a peptide for modulating angiogenesis with applications in cancer and ophthalmology, and BioGlucagon, a therapy for low sugar events in diabetes. The company has collaboration arrangements with Centre National de la Recherche Scientifique and Avion Pharmaceuticals LLC for the development and licensing of peptide technology and products. ImmuPharma was founded in 1999.

Frequently Asked Questions

What is ImmuPharma- Plc's ticker?

ImmuPharma- Plc's ticker is IMM

What exchange is ImmuPharma- Plc traded on?

The company's shares trade on the LSE stock exchange

Where are ImmuPharma- Plc's headquarters?

They are based in London, England

How many employees does ImmuPharma- Plc have?

There are 11-50 employees working at ImmuPharma- Plc

What is ImmuPharma- Plc's website?

It is https://www.immupharma.co.uk/

What type of sector is ImmuPharma- Plc?

ImmuPharma- Plc is in the Healthcare sector

What type of industry is ImmuPharma- Plc?

ImmuPharma- Plc is in the Biotechnology industry

Who are ImmuPharma- Plc's peers and competitors?

The following five companies are ImmuPharma- Plc's industry peers:

- Akebia Therapeutics

- Fair Isaac Corporation

- Eyenovia Inc

- Champions Oncology

- Aduro BioTech Inc